You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,399,484


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,399,484
Title:Combination therapy for treating HCV infection
Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.
Inventor(s): Huang; David (NY, NY), Steinmann; Gerhard Gustav (Erbach, DE), Stern; Jerry Oscar (New Fairfield, CT)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:12/560,752
Patent Claims:1. A method of treating hepatitis C viral (HCV) infection in a patient comprising the step of administering to the patient a therapeutic combination comprising: (a) a compound of the following formula (1) or a pharmaceutically acceptable salt thereof: ##STR00005## (b) interferon alpha; and (c) ribavirin.

2. The method according to claim 1, wherein the HCV infection is genotype 1.

3. The method according to claim 1, wherein said patient is a treatment-naive patient.

4. The method according to claim 1, wherein said patient is non-responsive to a combination therapy using ribavirin and an interferon alpha.

5. The method according to claim 1, wherein the HCV-RNA levels of said patient are reduced to a less than detectable level as a result of the treatment.

6. The method according to claim 1, wherein said therapeutic combination is administered for at least 4 weeks.

7. The method according to claim 1, wherein said therapeutic combination is administered for at least 12 weeks.

8. The method according to claim 1, wherein said therapeutic combination is administered for at least 24 weeks.

9. The method according to claim 1, wherein compound (1) or a pharmaceutically acceptable salt thereof is administered at a dosage of at least 40 mg per day.

10. The method according to claim 1, wherein compound (1) or a pharmaceutically acceptable salt thereof is administered at a dosage between about 40 mg per day and about 300 mg per day.

11. The method according to claim 1, wherein compound (1) or a pharmaceutically acceptable salt thereof is administered at a dosage between about 48 mg per day and about 240 mg per day.

12. The method according to claim 1, wherein compound (1) is administered in the form of its sodium salt.

13. The method according to claim 1, wherein said ribavirin is administered at a dosage between about 400 mg/day and about 1200 mg/day.

14. The method according to claim 1, wherein said ribavirin is administered at a dosage between about 800 mg/day and about 1200 mg/day.

15. The method according to claim 1, wherein said interferon alpha is administered once a week.

16. The method according to claim 1, wherein said interferon alpha is a pegylated interferon alfa.

17. The method according to claim 16, wherein said pegylated interferon alfa is pegylated interferon alfa-2a or pegylated interferon alfa-2b.

18. The method according to claim 16, wherein the pegylated interferon alfa is pegylated interferon alfa-2b administered at a dosage of about 0.5 .mu.g/kg/week to about 2 .mu.g/kg/week.

19. The method according to claim 16, wherein the pegylated interferon alfa is pegylated interferon alfa-2b administered at a dosage of about 1 .mu.g/kg/week to about 2 .mu.g/kg/week.

20. The method according to claim 16, wherein the pegylated interferon alfa is pegylated interferon alfa-2b administered at a dosage of about 1.5 .mu.g/kg/week.

21. The method according to claim 16, wherein the pegylated interferon alfa is pegylated interferon alfa-2a administered at a dosage of about 90 to 200 .mu.g/week.

22. The method according to claim 16, wherein the pegylated interferon alfa is pegylated interferon alfa-2a administered at a dosage of about 180 .mu.g/week.

23. The method according to claim 1, wherein the HCV infection is genotype 1, the patient is non-responsive to a combination therapy using ribavirin and an interferon, the compound (1) or a pharmaceutically acceptable salt thereof is administered at a dosage between about 48 mg per day and about 240 mg per day and wherein said interferon alfa is pegylated interferon alfa-2a or pegylated interferon alfa-2b.

24. The method according to claim 23, wherein compound (1) is administered in the form of its sodium salt.

25. The method according to claim 1, comprising administering to the patient compound (1) or a pharmaceutically acceptable salt thereof once a day; ribavirin twice a day; and interferon alfa once a week.

26. The method according to claim 23, comprising administering to the patient compound (1) or a pharmaceutically acceptable salt thereof once a day; ribavirin twice a day; and interferon alfa once a week.

27. The method according to claim 1, wherein there is no emergence of HCV variants that encode HCV NS3 protease amino acid substitutions at one or more of: R155, D168, or A156.

28. A kit comprising: (a) a first pharmaceutical composition comprising a compound of the following formula (1) or a pharmaceutically acceptable salt thereof: ##STR00006## (b) a second pharmaceutical composition comprising interferon alpha; and (c) a third pharmaceutical composition comprising ribavirin.

Details for Patent 8,399,484

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2028-09-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2028-09-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2028-09-17
Hoffmann-la Roche Inc. PEGASYS COPEGUS COMBINATION PACK peginterferon alfa-2a and ribavirin 125083 06/04/2004 ⤷  Try a Trial 2028-09-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.